arrow
E

Elizabeth R. Gerstner

Harvard University
H指数:59
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor-infiltrating lymphocyte therapy generated from melanoma brain metastasis: Proof-of-concept for CNS-derived cellular immunotherapy
2025-12-150
PRE
Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma
2025-12-150
PRE
ALLIANCE A071601: PHASE II TRIAL OF BRAF/MEK INHIBITION IN RECURRENT PAPILLARY CRANIOPHARYNGIOMAS

联盟A071601:BRAF/MEK抑制在复发性乳头状颅咽管瘤中的II期试验

2025-11-010
PRE
Prognostic significance of contrast enhancement in newly diagnosed grade 2IDH-mutant glioma

对比增强在 newly diagnosed grade 2 IDH-mutant glioma 中的预后意义

2025-11-010
PRE
Integrated multiomic profiling identifies genomic and immune microenvironmental changes as candidate resistance mechanisms to PD-1 blockade in high-grade meningiomas

整合多组学分析鉴定出基因组改变和免疫微环境变化为高级别脑膜瘤对PD-1阻断治疗的候选耐药机制

2025-11-010
OAAI
CERN 09-02: A PHASE 2 TRIAL OF CARBOPLATIN AND BEVACIZUMAB FOR RECURRENT ADULT EPENDYMOMA

CERN 09-02:一项关于卡铂和贝伐珠单抗治疗复发性成人室管膜瘤的II期临床试验

2025-11-010
OAAI
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells

间皮素是一种存在于人类脑膜瘤表面的抗原,并且可以被CAR T细胞有效靶向。

2025-11-010
OAAI
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells

Ramapriyan, R.; Barker, F.G., 2nd; Richardson, L.G.; Sun, J.; Vandecandelaere, G.; Shim, J.M.; De Vlaminck, G.; Gaffey, M.; Grewal, E.P.; Tazhibi, M.; et al. 纤维蛋白是存在于人类脑膜瘤表面的抗原,并且可以被CAR T细胞有效靶向。Neuro-Oncology 2025, noaf155. [Google Scholar] [CrossRef]

2025-07-015
PRE
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes

伊沃西尼布治疗IDH1-mutant胶质瘤,2-4级: 耐受性,反应预测因子和结果

2024-12-191
OAAI
ALLIANCE A071401: GENOMICALLY GUIDED PHASE II TRIAL OF ABEMACICLIB IN PATIENTS WITH GRADE 2/3 MENINGIOMAS HARBORING SOMATIC NF2 OR CDK PATHWAY ALTERATIONS
2024-11-110
PRE
REAL WORLD EXPERIENCE USING THE IDH INHIBITOR IVOSIDENIB IN IDH MUTANT GLIOMA: TOLERABILITY AND OUTCOMES
2024-11-110
PRE